January 20, 2017
Where do you stand against influenza
Flu, or influenza, is a very contagious, acute, viral respiratory infection. Influenza viruses vary in a high degree. The extent…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
January 20, 2017
Sanofi’s M&A misses frustrate some investors in drugmaker
For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.
The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.
January 20, 2017
Bristol-Myers not asking for faster Opdivo/Yervov approval for first-line lung cancer in U.S.
Bristol-Myers Squibb said on Thursday that it won’t seek an accelerated approval for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S.
January 20, 2017
Abzena nets $300 million for its ThioBridge technology
Abzena has made a deal with a San Diego-based biopharmaceutical company for Abzena’s novel site–specific ThioBridge antibody drug conjugate (ADC) linker technology, which links antibodies and other proteins to drugs. The $300 million worth agreement with the…
January 20, 2017
Cerenis satisfied with Q4 2016, expects good news from clinic in Q1 2017
French company Cerenis Therapeutics has seen some good things happen in the previous period in clinics by finalizing certain studies and getting FDA’s approval to kick some off. Also certain results showed progress and the company has reported solid cash position for the end of the year.
January 20, 2017
Japanese MHLW OK’s Bayer’s cancer drug
Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review to Bayer Yakuhin for regorafenib in the second-line…
January 19, 2017
FDA approves Allergan’s skin disease drug
U.S. Food and Drug Administration (FDA) has approved Allergan’s Rhofade skin desease cream, a topical treatment of persistent facial erythema (redness)…
January 19, 2017
Anavex secures cash to study Anavex 2-73 for Rett syndrome
Anavex has ensured most of the cash for a U.S. multicentre Phase 2 clinical trial of Rett syndrome treatment Anavex2-73.
January 19, 2017
NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit
NeuroVive Pharmaceutical’s abstract with novel preclinical cancer data related to the company’s sanglifehrin-based compounds has been accepted for presentation at…
January 19, 2017
Summit Therapeutics’s R&D adviser becomes COO, President of Research Development
Summit Therapeutics has named its research and development adviser Dr David Roblin as new Chief Operating Officer (COO) and President of Research Development.